Radiotherapy in the treatment of gastrointestinal stromal tumor by Knowlton, Christin A. et al.
Radiotherapy in the treatment
of gastrointestinal stromal
tumor
Christin A. Knowlton,1 Luther W. Brady,1
Rebecca C. Heintzelman2 
1Department of Radiation Oncology;
2Department of Pathology and
Laboratory Medicine, Drexel University
College of Medicine, Philadelphia, PA,
USA
Abstract 
Gastrointestinal stromal tumors (GISTs) are
uncommon mesenchymal tumors of the gas-
trointestinal tract. Up to one-third of GISTs are
malignant  with  a  high  rate  of  metastasis.
Surgical resection is the mainstay of care for
patients  with  resectable  disease.  Imatinib
mesylate, a selective tyrosine kinase inhibitor,
is the current standard of care for GISTs that
cannot be completely resected or in cases of
metastatic  GIST.  Although  often  overlooked,
radiation therapy is a viable option for select
patients with GIST. We report the case of a
patient with unresectable GIST who was treat-
ed with local radiotherapy and achieved long-
term response. We also present a review of the
literature regarding the use of radiotherapy in
the treatment of GIST. GIST has been shown to
be a radiosensitive tumor. Radiotherapy can
offer long-term local control and should be con-
sidered in the adjuvant or palliative setting.
The role of radiotherapy delivered concurrent-
ly with imatinib in the treatment of GIST may
warrant further investigation.
Introduction
Gastrointestinal stromal tumors (GISTs) are
uncommon  mesenchymal  tumors  that  arise
from the precursors to the interstitial cells of
Cajal in the wall of the gastrointestinal tract. In
the United States, approximately 4500 to 6000
cases of GIST are diagnosed each year. Up to
one-third of cases of GIST are malignant with
a high rate of metastasis, often to the retro -
peritoneum  and  liver.1 Prior  to  1983,  GISTs
were usually classified as leiomyomas or leio  -
myosarcomas.2 Immunohistochemical studies
have demonstrated that GISTs do not show a
differentiation to smooth muscle but instead
are a heterogeneous group of tumors with var-
ied differentiation and with mutation in the c-
KIT  receptor  tyrosine  kinase  or,  less  often,
platelet-derived  growth  factor  receptor-alpha
(PDGFRA).3,4  GIST has three main histologic
patterns:  spindle  cell  type  (70%),  epitheliod
cell type (20%) or a mixture of both (Figure 1).
Over 95% of GISTs show immunopositivity for
CD117 (KIT) (Figure 2). Other common mark-
ers for GIST include CD34 and smooth muscle
actin (SMA), which are expressed in approxi-
mately  70%  and  40%  of  GISTs  respectively
(Figure 3).5
For  patients  with  GIST,  complete  surgical
resection  offers  the  greatest  chance  for
increased  disease-free  survival.  Imatinib
mesylate, a selective tyrosine kinase inhibitor
of c-KIT and PDGRA (as well as BCR-ABL in
chronic myelogenous leukemia), is the current
standard of care for GIST that cannot be com-
pletely resected. Eighty-five to ninety percent
of patients experience meaningful tumor con-
trol and prolonged overall survival with ima-
tinib. Tumors may demonstrate primary resist-
ance or develop secondary resistance to ima-
tinib. Sunitinib, a multi-targeted inhibitor of
tyrosine kinase, has recently been approved for
use in patients with imatinib-refractory GIST.3
Both imatinib and sunitinib are classified as
tyrosine kinase inhibitors (TKI). In addition,
some patients are not able to tolerate imatinib
or  sunitinib,  which  are  oral  agents,  due  to
sequelae  from  their  disease  or  side  effects
from the medication. 
While  often  overlooked,  radiation  therapy
may also be a useful treatment modality for
select patients with GIST. The benefit of adju-
vant or primary radiation therapy in the treat-
ment of GIST remains unclear. This is likely
due to several factors, including the rarity of
the disease and the limited dose tolerance of
the  gastrointestinal  organs.  We  present  the
case of a patient with unresectable GIST who
was diagnosed prior to the widespread use of
imatinib for treatment of GIST.  The patient
was treated with external beam radiation ther-
apy at our institution.  We also review the liter-
ature addressing the role of radiotherapy in
the treatment of GIST.
Case Report
At our institution, a 37-year-old man under-
went surgery for acute intestinal obstruction.
Abnormal tissue was seen in the wall of the
antrum  and  small  intestine.    Several  local
lymph  nodes  were  found  to  be  involved.
Although the frozen section was read as con-
sistent with Hodgkin’s disease, the final patho-
logic diagnosis was eosinophilic gastroenteri-
tis.  The  area  of  disease  was  deemed  unre-
sectable;  debulking  surgery  was  performed.
The patient was symptom-free for four years,
at which time he developed recurrent symp-
toms of obstruction plus a palpable abdominal
mass.  Excisional  biopsy  of  a  mass  in  the
antrum was performed, with similar histologic
findings.  Additional  review  of  the  pathology
concluded that the initial diagnosis was incor-
rect. The tumor was determined to be a GIST.
The  area  of  disease,  including  most  of  the
stomach, was treated with a 1.5 cm margin to
36 Gy delivered in 24 fractions of 1.5 Gy each
with  anteroposterior/posteroanterior  (AP/PA)
fields (Figure 4A and 4B). Radiotherapy was
well tolerated. The patient’s gastroenterologi-
cal symptoms resolved and he did not experi-
ence any late term toxicity from treatment. He
did  well  and  was  clinically  disease-free  on
imaging  and  physical  examination  until  he
was  diagnosed  with  rectal  adenocarcinoma
almost 20 years later. He died later that year
from multiple medical comorbidities without
recurrence of the GIST.
Discussion
Only a small number of published studies
regarding the treatment of GIST address radia-
tion therapy. Several have shown that adjuvant
radiotherapy may be a useful modality in the
treatment of GISTs that cannot be completely
resected.  At  Princess  Margaret  Hospital
(Toronto,  ON),  10  of  50  patients  with  GIST
treated between 1989 and 1998 received radio-
therapy.6 They were not treated with chemo  -
therapy.  Two  received  preoperative  radiation
treatment for a fixed mass. Eight patients were
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[Rare Tumors 2011; 3:e35] [page 111]treated postoperatively due to residual, fixed
tumor.  Median  postoperative  radiation  dose
was 45 Gy in 1.8 fractions. Long-term local con-
trol within the radiation field was achieved in
six  of  nine  evaluable  patients  who  received
radiation  therapy.  This  case  series  provides
evidence that GIST is a radiosensitive tumor.
A  case  study  published  by  Pollack  et  al.7
demonstrates  that  radiotherapy  may  benefit
patients  with  GIST  that  have  microscopic
residual disease. The patient had a 7 cm rectal
GIST  removed  in  piecemeal  fashion  with
microscopically positive margins. She refused
further surgery and was therefore treated with
radiotherapy,  including  36  Gy  to  the  whole
pelvis,  followed  by  an  additional  9 Gy  to  a
reduced pelvic field plus a 5.4 Gy conedown to
the tumor bed with a 2 cm margin, for a total of
50.4 Gy. At follow-up of two years, the patient
was disease-free. An additional case study pub-
lished in Italy in 2002 describes a case of GIST
of the rectum treated with abdominoperineal
resection with a microscopically positive mar-
gin.8 The patient received adjuvant radiothera-
py of 50 Gy. At 32 months following surgery, the
patient  was  without  disease.  These  studies
suggest  that  postoperative  radiation  therapy
for residual microscopic disease may enhance
local control. 
In  contrast,  a  retrospective  study  from
Massachusetts General Hospital does not sup-
port the use of radiotherapy in cases of incom-
plete resection of GIST.9 The study includes 70
patients with GIST treated between 1973 and
1998.  Twenty of these patients received radia-
tion therapy, largely for intermediate- to high-
grade tumors following incomplete resection
and no evidence of metastasis. Radiation ther-
apy provided no advantage in disease-specific
survival. Furthermore, patients who received
radiotherapy showed a significantly increased
rate  of  recurrence  (hazard  ratio=5.40;
P=.002). However, the authors note that those
who  received  radiotherapy  likely  had  more
aggressive disease. Also, the radiation treat-
ment was not standardized and no information
is provided regarding the dose and radiation
technique. 
A case study from Japan published in 2001
indicates that radiotherapy may also be useful
as a component of treatment for large metasta-
tic lesions.10 The patient underwent total gas-
trectomy, distal pancreatectomy, and splenec-
tomy in 1990 for GIST. In 1993, she presented
with  an  11  cm  retroperitoneal  metastasis,
which was treated with radiotherapy and con-
comitant  chemotherapy  (carboplatin  and
epirubicin). A total of 51 Gy in 1.5 Gy fractions
was delivered to the tumor. The patient’s ele-
vated serum lactate dehydrogenase level (2142
IU/L) began to decrease following the initia-
tion  of  radiotherapy  and  was  within  normal
range at the end of the radiation treatment
course. CT scan immediately after completion
of radiotherapy indicated decreased density of
the  tumor.  In  addition,  the  patient  received
four injections of OK432, an immunotherapeu-
tic  agent,  following  the  conclusion  of  radio-
therapy. Six years after treatment, the tumor
had markedly decreased density and measured
20 mm, demonstrating excellent results. This
case  supports  the  use  of  radiotherapy  as  a
component of palliative treatment of an isolat-
ed metastatic lesion. 
A more recent abstract by Hurwitz et al.from
Royal  Marsden  Hospital  presented  in  2008
described  their  experience  with  palliative
radiotherapy  for  locally  progressive  and/or
symptomatic metastatic GISTs.11 Most patients
received 30 Gy in 10 fractions. Eleven of 12
patients  experienced  improvement  in  symp-
toms. Treatment is described as well-tolerated,
with most toxicities being grade 1 or 2.
Two  additional  published  case  studies
address the use of radiotherapy delivered con-
comitantly with imatinib.  In one case study
from  Turkey,12 the  patient  presented  with  a
15×10 cm mass at the area of the sacrum and
coccyx with invasion into the rectum. Multiple
liver lesions were also seen. The pelvic mass
was  incompletely  resected;  histopathological
and  immunohistochemical  examination  de  -
monstrat  ed GIST with expression of c-KIT. The
residual tumor was irradiated to 54 Gy in 2 Gy
fractions with concomitant imatinib. Dramatic
regression of the mass and alleviation of pain
occurred  following  radiotherapy.  Treatment
with imatinib was continued. CT scans at two
and  four  months  post-radiotherapy  showed
continued regression of the pelvic tumor; the
liver lesions remained stable. The pelvic tumor
regressed completely at 27 months after the
completion of radiotherapy. At 37 months, the
liver lesions began to progress. The dose of
imatinib  was  increased;  however,  the  liver
lesions continued to increase in size. There
was no evidence of recurrence in the radiation
field. We can conclude that the long-term local
control of the pelvic mass was due to the radio-
therapy. 
A second case study by Ciresa et al. illus-
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Figure  1.  Gastrointestinal  stromal  tumor
(GIST) of the stomach with spindle cells in
a fasicular pattern (H&E stain; magnifica-
tion 100x).
Figure 2. Spindle cell GIST showing dif-
fuse  immunopositivity  for  CD117  (KIT)
(magnification 400x).
Figure  3.  Spindle  cell  GIST  with  strong
immunostaining for CD34 (magnification
400x).
Figure 4. Digitally reconstructed radiographs demonstrating a re-creation of the antero-
posterior (A) and posteroanterior (B) radiation treatment fields.
A BCase Report
trates  the  use  of  concomitant  pre-operative
radiotherapy and imatinib.13 The patient pre-
sented with a 4.7cm rectal mass with exten-
sion to the anal canal. Biopsy revealed a GIST,
positive for c-KIT. The entire mesorectum was
included in the treatment field. Treatment was
stopped at 37.8 Gy due to grade 3 hematologic
toxicity  and  grade  2  proctitis.  There  was  a
marked clinical response on physical examina-
tion  and  imaging.  The  patient  underwent  a
sphincter-sparing low anterior resection with a
pathologic  complete  response.  In  these  two
cases, concomitant radiotherapy and imatinib
were delivered safely. 
Our institutional experience demonstrates
that  external  beam  radiotherapy  may  be  a
viable option for local control of unresectable
GIST.  Our  patient’s  excellent  long-term  local
control indicates that GIST is a radiosensitive
tumor. This is also seen in the small number of
published studies that demonstrate the effec-
tiveness of radiotherapy in the treatment of
residual and metastatic GIST. Radiation thera-
py, therefore, may be a useful tool in the man-
agement  of  GIST.  Radiation  therapy  may  be
especially valuable for patients who cannot tol-
erate imatinib or sunitinib or who have TKI-
resistant disease.  Radiotherapy should be con-
sidered for patients with unresectable disease,
with gross or microscopic residual disease fol-
lowing surgery or with recurrent or metastatic
disease requiring palliation.  For symptomatic
patients,  palliative  radiotherapy  may  offer
relief with minimal acute side effects. There is
currently an open trial at Helsinki University
looking at the role of radiotherapy for pallia-
tion  in  patients  with  progressive  metastatic
disease during or after treatment with a TKI
(http://clinicaltrials.gov/ct2/show/NCT005159).
In addition, the use of radiation therapy con-
currently  with  imatinib  holds  promise  for
patients  with  unresectable  tumor.  Further
investigation is warranted.
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